<?xml version='1.0' encoding='utf-8'?>
<document id="11061574"><sentence text="Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction."><entity charOffset="74-83" id="DDI-PubMed.11061574.s1.e0" text="talinolol" /></sentence><sentence text="P-Glycoprotein is an efflux pump in many epithelial cells with excretory function" /><sentence text=" It has been demonstrated that rifampin (INN, rifampicin) induces P-glycoprotein, particularly in the gut wall"><entity charOffset="31-39" id="DDI-PubMed.11061574.s3.e0" text="rifampin" /><entity charOffset="41-44" id="DDI-PubMed.11061574.s3.e1" text="INN" /><entity charOffset="46-56" id="DDI-PubMed.11061574.s3.e2" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.11061574.s3.e0" e2="DDI-PubMed.11061574.s3.e0" /><pair ddi="false" e1="DDI-PubMed.11061574.s3.e0" e2="DDI-PubMed.11061574.s3.e1" /><pair ddi="false" e1="DDI-PubMed.11061574.s3.e0" e2="DDI-PubMed.11061574.s3.e2" /><pair ddi="false" e1="DDI-PubMed.11061574.s3.e1" e2="DDI-PubMed.11061574.s3.e1" /><pair ddi="false" e1="DDI-PubMed.11061574.s3.e1" e2="DDI-PubMed.11061574.s3.e2" /></sentence><sentence text=" We therefore hypothesized that rifampin affects pharmacokinetics of the P-glycoprotein substrate talinolol, a beta1-blocker without appreciable metabolic disposition but intense intestinal secretion in human beings"><entity charOffset="32-40" id="DDI-PubMed.11061574.s4.e0" text="rifampin" /><entity charOffset="98-107" id="DDI-PubMed.11061574.s4.e1" text="talinolol" /><pair ddi="false" e1="DDI-PubMed.11061574.s4.e0" e2="DDI-PubMed.11061574.s4.e0" /><pair ddi="false" e1="DDI-PubMed.11061574.s4.e0" e2="DDI-PubMed.11061574.s4.e1" /></sentence><sentence text="" /><sentence text="Pharmacokinetics of talinolol (a single dose of 30 mg administered intravenously or 100 mg administered orally for 7 days) and duodenal expression of the MDR1 gene product P-glycoprotein as assessed by reverse transcriptase-polymerase chain reaction of the MDR1-messenger ribonucleic acid, by immunohistochemistry and Western blot analysis were analyzed before and after coadministration of rifampin (600 mg per day for 9 days) in 8 male healthy volunteers (age 22 to 26 years)"><entity charOffset="20-29" id="DDI-PubMed.11061574.s6.e0" text="talinolol" /><entity charOffset="391-399" id="DDI-PubMed.11061574.s6.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.11061574.s6.e0" e2="DDI-PubMed.11061574.s6.e0" /><pair ddi="false" e1="DDI-PubMed.11061574.s6.e0" e2="DDI-PubMed.11061574.s6.e1" /></sentence><sentence text="" /><sentence text="During rifampin treatment, the areas under the curve of intravenous and oral talinolol were significantly lower (21% and 35%; P &lt; "><entity charOffset="7-15" id="DDI-PubMed.11061574.s8.e0" text="rifampin" /><entity charOffset="77-86" id="DDI-PubMed.11061574.s8.e1" text="talinolol" /><pair ddi="false" e1="DDI-PubMed.11061574.s8.e0" e2="DDI-PubMed.11061574.s8.e0" /><pair ddi="false" e1="DDI-PubMed.11061574.s8.e0" e2="DDI-PubMed.11061574.s8.e1" /></sentence><sentence text="05)" /><sentence text=" Treatment with rifampin resulted in a significantly increased expression of duodenal P-glycoprotein content 4"><entity charOffset="16-24" id="DDI-PubMed.11061574.s10.e0" text="rifampin" /></sentence><sentence text="2-fold (2" /><sentence text="9, 6" /><sentence text="51) (Western blot) and messenger RNA was increased in six of the eight volunteers" /><sentence text=" P-Glycoprotein expression in biopsy specimens of gut mucosa correlated significantly with the systemic clearance of intravenous talinolol (rs = 0"><entity charOffset="129-138" id="DDI-PubMed.11061574.s14.e0" text="talinolol" /></sentence><sentence text="74; P &lt; " /><sentence text="001)" /><sentence text="" /><sentence text="Rifampin induces P-glycoprotein-mediated excretion of talinolol predominantly in the gut wall"><entity charOffset="0-8" id="DDI-PubMed.11061574.s18.e0" text="Rifampin" /></sentence><sentence text=" Moreover, clearance of talinolol from the blood into the lumen of the gastrointestinal tract may be predicted by the individual intestinal P-glycoprotein expression"><entity charOffset="24-33" id="DDI-PubMed.11061574.s19.e0" text="talinolol" /></sentence><sentence text=" Thus we describe a new type of steady-state drug interaction affecting compounds that are subject to transport rather than metabolism" /><sentence text="" /></document>